| | |
|
Visit Our Sponsors...  In 1990, Ortho Biotech was established as the first biotechnology subsidiary of Johnson & Johnson, a major health-care company. As a company engaged in the business of innovative research, Ortho Biotech has access to research and development at the R. W. Johnson Pharmaceutical Research Institute, with research teams in the United States, Canada, Switzerland, and many other countries. Ortho Biotech acquired the rights to develop and market recombinant human erythropoietin. In the United States, Ortho Biotech markets recombinant human erythropoietin under the tradename PROCRIT® (Epoetin alfa). It treats anemia associated with cancer chemotherapy for non-myeloid malignancies; HIV-infected AZT-treated patients; and early kidney disease patients not yet on dialysis. It also is used for the treatment of anemic patients scheduled to undergo elective, non-cardiac, non-vascular surgery. All information is intended for your general knowledge only and is not a substitute for medical advice or treatment for specific medical conditions. Specialty Physicians Alliance disclaims the creation of a physician/patient relationship and responsibility for any and all liability for injury and/or other damages which result from an individual using the materials provided on the Internet. Use of this online service is subject to the attached disclaimer. © 1998 Specialty Physicians Alliance. All rights reserved. If you have questions or comments please contact webmaster@spa-ortho.com |
||||||||||||||||||||||||||||||||
